Vitura SA (VTR) AI Stock Analysis

• Market Cap: €67.22M
• Dividend Yield: N/A
• Average Volume (3M): 364.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: -7.84%
• EPS Growth: 71.75%
• Country: FR
• Employees: 2
• Sector: Services
• Sector Strength: N/A
• Industry: REIT - Office
• EPS (TTM): N/A
• Shares Outstanding: 17,087,708
• 10 Day Avg. Volume: 318
• 30 Day Avg. Volume: 364
• PEG Ratio: -0.22
• Price to Book (P/B): 0.25
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 17.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: €5.00 ▼(-9.91% Downside)
• Action: Reiterated Date: 11/30/25
• Date: Action: Reiterated 11/30/25

Vitura SA's overall stock score of 43 reflects significant challenges, primarily driven by poor financial performance with persistent net losses, declining revenue, and high leverage. Technical analysis further supports a bearish outlook with a consistent downtrend and weak momentum. Valuation metrics offer no positive offset due to negative earnings and lack of dividend yield.

Positive Factors

Innovation and R&D

Vitura SA's commitment to R&D fosters innovation, enabling the development of advanced medical products and solutions, which can lead to sustainable competitive advantages and long-term growth.

Negative Factors

Declining Revenues

Declining revenues indicate potential challenges in maintaining market share and demand for products, which can impact long-term financial health and growth prospects.

Vitura SA Business Overview & Revenue Model

Company Description

Vitura SA (VTR) is a leading company operating in the healthcare and pharmaceuticals sector, specializing in the development, manufacturing, and distribution of innovative medical products and solutions. The company focuses on enhancing patient ca...

Read more

Vitura SA (VTR) is a leading company operating in the healthcare and pharmaceuticals sector, specializing in the development, manufacturing, and distribution of innovative medical products and solutions. The company focuses on enhancing patient ca...

How the Company Makes Money

Vitura SA generates revenue through multiple streams, primarily from the sale of its pharmaceutical products and medical devices. The company has established a strong market presence through strategic partnerships with healthcare providers, hospit...

Read more

Vitura SA generates revenue through multiple streams, primarily from the sale of its pharmaceutical products and medical devices. The company has established a strong market presence through strategic partnerships with healthcare providers, hospit...

Vitura SA Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.14M	57.87M	76.61M	72.78M	84.92M	84.88M
Gross Profit	36.88M	32.91M	50.43M	44.14M	63.67M	63.32M
EBITDA	17.07M	26.85M	-166.93M	41.01M	45.52M	54.89M
Net Income	-199.38M	-243.00M	-239.85M	-4.18M	36.93M	16.09M
Balance Sheet
Total Assets	936.33M	940.47M	1.40B	1.62B	1.66B	1.55B
Cash, Cash Equivalents and Short-Term Investments	23.36M	13.49M	11.72M	15.17M	57.48M	62.84M
Total Debt	643.20M	644.20M	855.10M	835.39M	833.49M	776.73M
Total Liabilities	678.38M	671.57M	883.93M	868.77M	890.52M	817.80M
Stockholders Equity	257.95M	268.91M	511.91M	755.44M	772.94M	734.32M
Cash Flow
Free Cash Flow	18.23M	3.83M	-17.45M	-22.70M	-69.37M	32.41M
Operating Cash Flow	22.40M	12.61M	12.04M	-9.36M	40.90M	42.64M
Investing Cash Flow	1.08M	-2.69M	-29.32M	-19.47M	-103.31M	-9.57M
Financing Cash Flow	-10.50M	-8.15M	13.83M	-13.48M	57.05M	-15.11M

Vitura SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:VTR, the sentiment is Positive. The current price of 5.55 is above the 20-day moving average (MA) of 3.86, above the 50-day MA of 3.83, and above the 200-day MA of 4.87, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 62.80 is Neutral, neither overbought nor oversold. The STOCH value of 90.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:VTR.

Vitura SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GFC	59 Neutral	€4.90B	9.41	4.93%	6.39%	3.84%	―
Sector *	55 Neutral	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
INEA	53 Neutral	€374.00M	75.52	―	8.06%	10.30%	―
EIFF	44 Neutral	€531.50M	-8.37	-10.94%	―	-6.82%	62.40%
VTR	43 Neutral	€67.22M	-2.58	-16.98%	―	-7.84%	71.75%